GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy.
Céline BoileauSeverine DeforgesAngélique PeretDidier ScavardaFabrice BartolomeiApril GilesNicolas PartoucheJustine GautronJulio ViottiHaley N JanowitzGuillaume PenchetCécile MarchalStanislas LagardeAgnès TrebuchonNathalie VilleneuveJulie RumiThomas MarissalRoustem KhazipovIlgam KhalilovFanny MartineauMarine MaréchalAnne LepineMathieu MilhDominique Figarella-BrangerEtienne DougySoutsakhone TongRomain AppayStéphane BaudouinAndrew MercerJared B SmithOlivier DanosRichard PorterChristophe MulleValérie CrépelPublished in: Annals of neurology (2023)
Our gene silencing strategy to knock down aberrant GluK2 expression demonstrates inhibition of chronic seizure in a mouse TLE model and IEDs in cultured slices derived from TLE patients. These results provide proof-of-concept for a gene therapy approach targeting GluK2 KARs for drug-resistant TLE patients. This article is protected by copyright. All rights reserved.